SCHEMBL5010336

SCHEMBL5010336

NCCCCC(N)C(=O)OC(=O)CCC(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSR P00390 2/20 0.52
FOLH1 Q04609 1/20 0.44
CYP2D6 P10635 1/20 0.44
NFKB1 P19838 1/20 0.44
BLM P54132 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
LMNA P02545 2/20 0.42
THRB P10828 2/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
PLG P00747 1/20 0.42
ALOX15 P16050 1/20 0.42
SLC6A2 P23975 1/20 0.42
RECQL P46063 1/20 0.42
SLC6A3 Q01959 1/20 0.42
CYP1A2 P05177 2/20 0.41
GABRR3 A8MPY1 1/20 0.41
GABRP O00591 1/20 0.41
GABRD O14764 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5010333 1.00 GSR (0.52) GSRFOLH1CYP2D6NFKB1BLM
SCHEMBL1191631 0.93 GSR (0.53) GSRFOLH1CYP2D6NFKB1CYP1A2
SCHEMBL5010331 0.93 GSR (0.53) GSRFOLH1CYP2D6NFKB1CYP1A2
SCHEMBL27632676 0.92 GSR (0.50) GSRFOLH1CYP2D6NFKB1BLM
SCHEMBL8836895 0.91 GSR (0.52) GSRFOLH1CYP2D6NFKB1CYP1A2
SCHEMBL8836488 0.91 GSR (0.52) GSRFOLH1CYP2D6NFKB1CYP1A2
Water SCHEMBL5501375 0.91 GSR (0.52) GSRFOLH1CYP2D6NFKB1CYP1A2
SCHEMBL21598211 0.90 LMNA (0.53) GSRFOLH1CYP2D6NFKB1BLM
SCHEMBL8759024 0.88 GSR (0.52) GSRFOLH1CYP2D6NFKB1BLM
SCHEMBL1065054 0.88 GSR (0.52) GSRFOLH1CYP2D6NFKB1BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080234222-A1 Charge Reversal of Polyion Complexes ROCHE MADISON INC. 2008-09-25 US disclosed
US-7396919-B1 Charge reversal of polyion complexes MIRUS BIO CORPORATION (US) 2008-07-08 US disclosed
EP-1209971-A4 CHARGE REVERSAL OF POLYION COMPLEXES MIRUS CORP (US) 2004-04-14 EP disclosed
US-20030236214-A1 Charge reversal of polyion complexes and treatment of peripheral occlusive disease WOLFF JON A (US) 2003-12-25 US disclosed
EP-1098632-A4 CHARGE REVERSAL OF POLYION COMPLEXES MIRUS CORP (US) 2002-09-04 EP disclosed
EP-1209971-A1 CHARGE REVERSAL OF POLYION COMPLEXES Mirus Corporation (US) 2002-06-05 EP disclosed
US-20020052335-A1 Charge reversal of polyion complexes MIRUS BIO CORPORATION 2002-05-02 US disclosed
EP-1098632-A1 CHARGE REVERSAL OF POLYION COMPLEXES Mirus Corporation (US) 2001-05-16 EP disclosed
WO-2001013723-A1 CHARGE REVERSAL OF POLYION COMPLEXES MIRUS CORPORATION (US) 2001-03-01 WO disclosed
WO-2000003694-A1 CHARGE REVERSAL OF POLYION COMPLEXES MIRUS CORPORATION (US) 2000-01-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052335-A1 Charge reversal of polyion complexes POLRMT, PARN, POLN GSR 1991/4885FOLH1 969/4885CYP2D6 4844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.